An observational study in Aortic Valve Stenosis, sponsored by AZ Sint-Jan AV. Recruiting at 12 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by AZ Sint-Jan AV · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Aortic Valve Stenosis with a site in Belgium — 11 open to participants now, 14 under way, 1 of them phase 3. Aortic Valve Stenosis · Belgium.
Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, this one is the 11th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2022, is one of 20 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 36th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →11 of the 47 studies in Aortic Valve Stenosis with a site in Belgium are open now. Recruiting first, the newest first:
Ole De Backer · Sites in Belgium, Denmark, Finland and 3 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Belgium, United States, Argentina and 20 more countries
Ages 6–11
Novartis Pharmaceuticals · Sites in Belgium, United States, Austria and 12 more countries
Ages 50–80
Université Libre de Bruxelles · Sites in Belgium
Ages 18+ · Healthy volunteers
National and Kapodistrian University of Athens · Sites in Belgium, Greece
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 27 interventional studies, 569 across the 20 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 47 have an industry lead sponsor. The 10 most frequent:
AZ Sint-Jan AV is the lead sponsor of 60 studies on the registry; 14 are open to participants now.
AZ Sint-Jan AV has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The current observational registry aims to evaluate in patients undergoing TAVI implantation:
The persistent growth in transcatheter aortic valve implantation (TAVI) calls for optimized early discharge programs to handle the increasing patient load. While access site bleeding and stroke rate have decreased with improved technologies and operators' experience, acquired conduction abnormalities necessitating prolonged rhythm-monitoring and permanent pacemaker (PPM) implantation have remained largely unchanged, and even up to 39.9% for some TAVI platforms. Prompt identification of patients necessitating PPM implantation leads to optimal patient care and use of resources. Conversely, prompt identification of patients with low -to no- risk for PPM post TAVI shortens their hospitalization and facilitates early and safe discharge.
Several baseline characteristics such as age, preexistent right bundle branch block (RBBB) and the use of self-expanding valves are associated with post-TAVI PPM implantation, but more practical and clinically more relevant parameters are needed with high negative and positive predictive values that could support clinical decision-making.
En passant rapid atrial pacing (RAP) immediately following TAVI has recently been reported to be a valuable tool in PPM risk stratification. The absence of Wenckebach phenomena post implantation at RAP up to 120/' has a negative predictive value for PPM of 98.7%.2 First use of RAP in routine practice at AZ Sint Jan Brugge can confirm these first results (unpublished data). This technique improves our clinical assessment and identification of low-risk patients for PPM suitable for safe early discharge, as well as high-risk patients requiring further rhythm monitoring and eventual PPM implantation.
The current observational registry aims to evaluate in patients undergoing TAVI implantation:
500 patients in sinus rhythm undergoing TAVI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients in sinus rhythm with TAVI
Procedure: RAP TAVI
All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
Positive and negative predictive value of RAP for PPM implantation post TAVI
Time frame: 1 month after TAVI
Permanent pacemaker implantation
Time frame: 1 month after TAVI
New conduction abnormalities
Time frame: within 1 week after TAVI
Duration of hospitalization
Time frame: 1 month after TAVI
Echocardiographic changes
Time frame: 1 month after TAVI
Stroke
Time frame: 1 month after TAVI
Major vascular bleeding
Time frame: 1 month after TAVI
New pericardial effusion
Time frame: 1 month after TAVI
All-cause mortality
Time frame: 1 month after TAVI
Started Sep 2022 (actual). Primary completion is estimated for Jun 2024, 21 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 21 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AZ Sint-Jan AV